Insider Selling: Pacira Biosciences Inc (NASDAQ:PCRX) Director Sells 1,300 Shares of Stock

Pacira Biosciences Inc (NASDAQ:PCRX) Director John P. Phd Longenecker sold 1,300 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $46.13, for a total transaction of $59,969.00. Following the sale, the director now owns 10,933 shares of the company’s stock, valued at approximately $504,339.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ PCRX traded up $0.26 during trading hours on Wednesday, reaching $46.30. 428,088 shares of the company were exchanged, compared to its average volume of 623,626. The company has a quick ratio of 3.32, a current ratio of 3.95 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $1.93 billion, a P/E ratio of 159.59, a P/E/G ratio of 2.07 and a beta of 1.17. Pacira Biosciences Inc has a 1 year low of $34.64 and a 1 year high of $49.50. The business’s 50 day simple moving average is $42.18 and its 200-day simple moving average is $41.19.

Pacira Biosciences (NASDAQ:PCRX) last issued its earnings results on Thursday, November 7th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.35. The firm had revenue of $104.69 million during the quarter, compared to analyst estimates of $104.88 million. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. The company’s quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter last year, the business earned $0.31 earnings per share. As a group, sell-side analysts anticipate that Pacira Biosciences Inc will post 0.71 earnings per share for the current year.

A number of analysts recently issued reports on PCRX shares. Needham & Company LLC restated a “buy” rating and set a $56.00 price objective on shares of Pacira Biosciences in a report on Thursday, November 7th. Cowen restated a “hold” rating and set a $41.00 price objective on shares of Pacira Biosciences in a report on Thursday, November 7th. Stifel Nicolaus set a $42.00 price objective on shares of Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, August 9th. Barclays raised their price objective on shares of Pacira Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, BTIG Research started coverage on shares of Pacira Biosciences in a report on Wednesday, November 6th. They set a “buy” rating and a $56.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $52.55.

A number of large investors have recently modified their holdings of PCRX. Amundi Pioneer Asset Management Inc. bought a new position in Pacira Biosciences during the first quarter worth about $65,000. Bowling Portfolio Management LLC bought a new position in Pacira Biosciences during the second quarter worth about $541,000. Steward Partners Investment Advisory LLC bought a new position in Pacira Biosciences during the second quarter worth about $71,000. Mesirow Financial Investment Management Equity Management boosted its position in Pacira Biosciences by 21.9% during the second quarter. Mesirow Financial Investment Management Equity Management now owns 109,611 shares of the company’s stock worth $4,767,000 after purchasing an additional 19,690 shares during the period. Finally, Aperio Group LLC bought a new position in Pacira Biosciences during the second quarter worth about $187,000. Hedge funds and other institutional investors own 99.13% of the company’s stock.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Recommended Story: Bollinger Bands

Insider Buying and Selling by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit